3-amino-pyrazole derivatives useful against tuberculosis
A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR 5 ; or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and C 1-2 alkyl; R 2 is selected from H, C 1-2 alkyl, OH, —CH 2 OH and C 1-2 alkoxy; Each R 3 is independently selected from OH, C 1-3 alkyl, F, Cl, Br, NH 2 , and C 1-3 alkoxy; R 4 is selected from C 1-3 alkyl and haloC 1-3 alkyl; R 5 is selected from H, C 1-3 alkyl and haloC 1-3 alkyl; R 6 and R 7 are either i) each independently selected from H, C 1-3 alkyl and C 1-3 alkoxy; or ii) R 6 and R 7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and R A is selected from H and C 1-3 alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
1. The compound (1S)-1-[5-({1-[(3-fluoro-2-pyridinyl)methyl]-1H-pyrazol-3-yl}amino)-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethanol, or a pharmaceutically acceptable salt thereof.
2. The compound: (1S)-1-[5-({1-[(3-fluoro-2-pyridinyl)methyl]-1H-pyrazol-3-yl}amino)-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethanol.
3. A compound according to claim 1 , for use in therapy.
4. A compound according to claim 1 , for use in the treatment of tuberculosis.
5. A method of treatment of tuberculosis in mammal, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1 .
6. A pharmaceutical composition comprising a compound according to claim 1 , and one or more pharmaceutically acceptable carriers, excipients or diluents.
7. The method of claim 5 wherein said mammal is human.